Targeting TROP2 in Oncology: Pan-Tumor Insights and the Next Wave of ADC Innovation

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Trump meets Xi: what's at stake? 19 min · 23 Sep 2026 · Business Daily

THE HERD – HOUR 3 – Caleb Williams Critics “Embarrassing Yourselves” 54 min · 23 Sep 2026 · The Herd with Colin Cowherd

BEST OF THE HERD – Giants Have A Jaxson Dart Dilemma | Joel Klatt: Arch Manning Needs To Play Better | Caleb Williams Critics “Embarrassing Yourselves” 1h 5m · 23 Sep 2026 · The Herd with Colin Cowherd

5 On It & Herb Howard shares a Bears report (Hour 3) 42 min · 23 Sep 2026 · Rahimi & Grote Show

Mike Florio talks Bears' quarterback conundrum, Caleb Williams injury discourse (Hour 2) 42 min · 23 Sep 2026 · Rahimi & Grote Show

The rape charge against 'looksmaxxer' Clavicular 20 min · 23 Sep 2026 · The Daily Aus

Report any issue

Source

Recorded18 Sep 2026

Publisherc.answersincme.com ↗

Handlerec:20439816

Show notes

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in